$22 Million

MediWound

Follow-on Offering

Lead Left Bookrunner, September 2017

Confidentially Marketed Public Offering

MediWound is developing its proteolytic enzyme technology to address severe burns, chronic and other hard-to-heal wounds. MediWound's first product, NexoBrid, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel, with plans for a launch in Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues.